Skip to main content
Equibles
CNTB logo

CNTB · Connect Biopharma Holdings Ltd

Track CNTB — free

Use CNTB with AI

Add company filings, earnings and prices to ChatGPT or Claude, then ask questions in your own chat.

Choose your app for step-by-step connection instructions. Sign in with Equibles when asked; no code or API key is needed.

Claude ChatGPT

After connecting, ask your AI to use Equibles to research CNTB.

Other apps & server URL
https://mcp.equibles.com/mcp
Gemini CLI setup
or ask here

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

See what you can ask in ChatGPT or Claude

All connection guides →
$2.04 -0.02 (-0.97%) At close · Sep 11
Russell 2000 member Rebalance outlook locked
Market Cap
$128.47M
Shares
62.97M

Price & Indicators

Indicators
Price
Panels
Event markers
20d MA 50d MA 200d MA Earnings Filing Insider Congress Investor day
Close$2.04 Open$2.07 Day$1.94–2.10 52W close$1.32–3.69 Avg vol 30d811K Short int2.0M · 3.2% float · 4.2d Short vol49% Last earningsJun 30, 2022 DataMar 2021–Sep 2026 Filing10-Q · Aug 12

Up next

Latest filing: 10-Q
filed Aug 12, 2026

Metrics snapshot

Useful current figures from the complete screener profile.

Revenue (TTM)
—
Trailing 12 months
Net income (TTM)
—
Trailing 12 months
Revenue growth YoY
—
Year over year
Operating margin
—
Trailing 12 months
P / E (TTM)
—
Trailing earnings
FCF yield
—
TTM · current market cap
Return on invested capital
—
Trailing 12 months
Net cash
—
Latest balance sheet
Dividend yield
—
Trailing 12 months
Shares change YoY
+13.3%
Year over year · more shares
Price change (1Y)
+17.0%
Trailing year
Short interest
3.2%
Latest settlement · 4.2 days to cover
View all 115 metrics

Equibles Rating

blended score · not investment advice
Overall
Strong Sell
SellHoldBuy
Technical Sell Momentum Very Weak Sentiment Neutral Fundamentals Poor Quant / Vol Very High
Market backdrop VIX 15.8 · calm Equity put/call 0.58
Technical
price trend
Sell
50 / 200-day cross No cross
Price vs 200-day avg −17%
below
Price vs 50-day avg −9%
below
RSI (14) 45
neutral
MACD trend Negative
52-week position 30%
mid-range
Momentum
relative strength
Very Weak
1-month return −20%
trailing
6-month return −26%
trailing
YTD return −28%
this year
Relative strength −44%
vs S&P · 6-mo
Sentiment
smart money
Neutral
Trend (MA cross) No cross
50d $2 › 200d $2 — 200d above 50d
Institutional flow Accumulating
+38% holders QoQ · +24 funds added
Insider flow Flat
No net insider activity over 90 days
Short interest Rising
3.16% of float · ▲ +9.3% MoM · 4.2 days cover
Volume signal Normal
Volume near normal
Institution breadth Multi-yr high
55 holders — near 1-yr high, broad support
Squeeze score 59
elevated · 0–100
Fundamentals
Poor
Revenue growth −100%
Y/Y
EPS growth −257%
Y/Y
Free cash flow $-51.6M
Quant / Vol
risk profile
Very High
Volatility 96%
annualized · 1-yr
Max drawdown −50%
past year
ATR 11.7%
of price · 14-day

Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.

Technicals

trend & momentum for long-term holders Sell
3 · 3 · 0
50 / 200-day cross
No cross Neutral
Price vs 200-day avg
−17% Bearish
Price vs 50-day avg
−9% Bearish
RSI (14)
45 Neutral
MACD trend
Negative Bearish
52-week position
30% Neutral
Market signals — smart money & positioning
Bullish · 2 of 6
Trend (MA cross) No cross
50d $2 › 200d $2 — 200d above 50d
Institutional flow Accumulating
+38% holders QoQ · +24 funds added
Insider flow Flat
No net insider activity over 90 days
Short interest Rising
3.16% of float · ▲ +9.3% MoM · 4.2 days cover
Volume signal Normal
Volume near normal
Institution breadth Multi-yr high
55 holders — near 1-yr high, broad support
Price context
position in its 52-week range
Range low $1 Now $2 · 30% Range high $4
vs 200-day avg -17% vs 50-day avg -9%

Illustrative technical + ownership context — a signal mix, not investment advice.

Key metrics

Earlier KPI extraction records exist, but do not meet the current evidence-completeness requirements. No current verified series is available. Earlier figures remain withheld until revalidated; this is not evidence that the company reports no KPIs.

Versus peers

Biotechnology — same industry group
Open screener →
Company Mkt cap YTD Rev growth Y/Y P/E Short % shares
CNTB
Connect Biopharma Holdings Ltd
this stock
$128.47M -27.7% -99.8% — 3.2%
VRTX
Vertex Pharmaceuticals Inc / Ma
 $130.64B +13.7% +46.2% 30.0 1.8%
REGN
Regeneron Pharmaceuticals, Inc.
 $80.46B +1.2% +20.8% 19.4 2.5%
ARGX
Argenx SE
 $61.22B +17.1% — — 2.0%
MRNA
Moderna, Inc.
 $57.48B +388.2% +4.3% — 9.8%

Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding

At a glance

key data from every section
Ownership
Institutional Holders Accumulating
Holders
55
% held
22.1%
Net QoQ
+870.3K sh
Top holder
Ikarian Capital, LLC
Held Float
View
Held by Funds
Fund positions
3
View
Short & Settlement
Short Interest Rising
Shares short
2.0M
Days to cover
4.2d
Change
+169.1K sh
View
Short Volume
Short vol %
49%
As of
Sep 11, 2026
Short Total
View
Fails to Deliver
FTD shares
660
Value
$1.4K
As of
Aug 11, 2026
View
Off-Exchange
Off-exchange %
56.5%
Week of
Aug 3, 2026
Off-exch Lit
View
Financials
Financials
Revenue (FY)
$64.0K
Net income (FY)
$-55.5M
EPS diluted
$-1.00
View
Filings
SEC Filings
Latest
8-K
Filed
Aug 12, 2026
This year
10
View
Proposed Sales
Value
$6.0M
Shares
2.0M
Filed
Nov 24, 2025
View
Earnings & Events
Earnings Calls
Last call
May 19, 2026
View

Performance

5D 20D 120D MTD YTD
CNTB +5.7% -19.7% -26.1% -7.3% -27.7%
SPY -1.2% -1.8% +17.8% -0.4% +12.1%
vs SPY +6.9% -17.9% -43.9% -6.9% -39.7%
Key facts CIK 1835268 CUSIP G23549101 13F (30d) 21 filings 21 filers Visit website Investor relations